Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
LCTX similar filings
- 30 Sep 21 Regulation FD Disclosure
- 15 Sep 21 Departure of Directors or Certain Officers
- 12 Aug 21 LINEAGE REPORTs SECOND QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS ADDITIONAL PROGRESS FROM CLINICAL CELL THERAPY PROGRAMS
- 21 Jul 21 Changes in Registrant's Certifying Accountant
- 16 Jun 21 Departure of Directors or Certain Officers
- 1 Jun 21 Lineage Cell Therapeutics Reports Additional Cases of Retinal Tissue Restoration In Dry Amd Patients Treated with Opregen® Rpe Cells
- 13 May 21 LINEAGE REPORTs FIRST QUARTER 2021 FINANCIAL RESULTS AND HIGHLIGHTS
Filing view
External links
Exhibit 16.1
July 20, 2021
Securities and Exchange Commission
100 F Street, N.E.
Washington, DC 20549-7561
Ladies and Gentlemen:
We have read Lineage Cell Therapeutics, Inc.’s statements included under Item 4.01 of its Form 8-K dated July 20, 2021, and are in agreement with the statements contained therein concerning our firm in response to Item 304(a) of Regulation S-K.
Very truly yours,
/s/ OUM & Co. LLP